Company: ABBV
Filing Date: 2025-02-18
Form Type: 424B5
Source: 0001104659-25-014554
Chunk: 15

Company: AbbVie Inc.
Filing Date: 2025-02-18
Form: 424B5
Chunk 15
---
 “our” and “us” mean AbbVie Inc. only.

#### General
AbbVie is issuing $ aggregate principal amount of 20 Notes. The 20 Notes will mature on , 20 . Interest on the 20 Notes will accrue at the rate of % per annum.

AbbVie is issuing $ aggregate principal amount of 20 Notes. The 20 Notes will mature on , 20 . Interest on the 20 Notes will accrue at the rate of % per annum.

AbbVie is issuing $ aggregate principal amount of 20 Notes. The 20 Notes will mature on , 20 . Interest on the 20 Notes will accrue at the rate of % per annum.

AbbVie is issuing $ aggregate principal amount of 20 Notes. The 20 Notes will mature on , 20 . Interest on the 20 Notes will accrue at the rate of % per annum.

The Notes will be issued in fully registered form and shall be in denominations of $2,000 and integral multiples of $1,000 in excess thereof.

In the future, AbbVie may, without the consent of the holders, increase the principal amount of any series of Notes offered hereby. The Notes of each series and any additional Notes of such series subsequently issued under the indenture will be treated as a single series or class for all purposes under the indenture, including, without limitation, waivers, amendments and redemptions; provided that, if any such additional Notes are not fungible with the existing Notes for United States federal income tax purposes, such additional Notes will have a separate CUSIP number.

The indenture limits neither the amount of debt that AbbVie may issue under the indenture, nor the amount of other debt or securities that AbbVie or any of its subsidiaries may issue. AbbVie may issue debt securities under the indenture from time to time in one or more series, each in an amount authorized prior to issuance. Other than the restrictions contained in the indenture on secured debt and sale/leaseback transactions described below under “Certain Covenants of AbbVie,” and the restrictions described below under “Consolidation, Merger and Sale of Assets,” the indenture does not contain any covenants or other provisions designed to protect holders of the debt securities in the event AbbVie participates in a highly leveraged transaction. In addition, the indenture does not limit AbbVie’s ability to guarantee any indebtedness of its subsidiaries or any other person.

We